BAFFR CAR T-Cell Therapy Shows Durable Responses, Manageable Toxicity for Patients With B-Cell Lymphomas Relapsing After or Ineligible for CD19-Targeted Treatments
Elizabeth Budde, MD, PhD, City of Hope National Medical Center, Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA, shares data on PMB-CT01, a novel autologous CAR-T cell therapy developed against B-cell activating factor (BAFF-R) for patients with B-cell lymphomas relapsing after or ineligible for CD-19 targeted treatments at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida.
“PMB-CT01 demonstrated an exceptionally favorable safety profile and 100% CR rate in r/r BNHL patients with poor-prognosis features, including CD19-negative disease and prior CD19 CAR T-cell therapy,” Budde et al concluded. “The durability of response at both dose levels supports the potential of BAFFR-CAR T cells as a promising therapeutic option in patients who are not candidates for or have relapsed after CD19-directed therapy.
“Continued enrollment and follow-up are ongoing, and updated clinical and correlative data will be presented at the meeting,” they added.
Source:
Budde E, Del Real M, Baird J, et al. BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease. Dec 6-9, 2025; Orlando, FL. Abstract: 268
